Received Jul 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | 343DD | — |
Early Dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a 14-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number 343DD, expiry date 30-APR-2026) for prophylaxis. Previously administered products included Menveo (first dose was given 3 years ago). On 10-JUL-2025, the patient received the 2nd dose of Menveo. On 10-JUL-2025, an unknown time after receiving Menveo, the patient experienced drug dose administration interval too short (Verbatim: Early Dose). The outcome of the drug dose administration interval too short was not applicable. Additional Information: GSK Receipt Date: 10-JUL-2025 The reporter reported that a patient that was fourteen and she received her second Menveo vaccine on the day of reporting. The one prior to that was given three years ago, so, the reporter wanted to know was ok if it was given three years in between but the reporter want to know if it did it need to be repeated at age sixteen like, would the second one count, because it was not 5 years apart. The healthcare professional stated that the first dose was given on the day of reporting and the patient first dose was given 3 years ago. The booster was given in less than recommended of 4 years which led to shortening of vaccination schedule.